治疗甲减还可能引发其他病情 只因优甲乐有副作用

2019-09-05 太阳尚远但一定会有 健康号

众所周知,目前对于甲状腺功能减退症,传统治疗上,还是以激素药物代替为主,尤其对于甲状腺腺体全部摘除者而言。那么,在甲减的临床应用药物中,最为广大病友常见的当属“优甲乐”。

众所周知,目前对于甲状腺功能减退症,传统治疗上,还是以激素药物代替为主,尤其对于甲状腺腺体全部摘除者而言。那么,在甲减的临床应用药物中,最为广大病友常见的当属“优甲乐”。

针对甲减药物“优甲乐”,很多患者在临床上经常会问到其长期服用的副作用,那么,今天北京北城甲状腺王克珍主任给大家讲一下,供大家参考。

优甲乐(左甲状腺素钠片)是目前甲减治疗最为流传的一种方式。不过要明确的是,优甲乐是激素代替药,并不是治疗甲减的药物,患者需长期服用来维持指标,中途一旦停药,指标会立即反弹。而患者更关心的是优甲乐的副作用,患者长期服用后往往会出现诸多的不适,这让甲减患者苦不堪言。

服用时间越长,副作用会越明显

1.药越吃越多,一旦停药立刻反弹:

优甲乐是不可能治疗甲减的,这在优甲乐研制之初,就已明确过的事实。优甲乐仅仅作为一种人工激素来补充甲状腺自身分泌的不足,因此,所有选择优甲乐来治疗的患者要有一个心理准备就是需要无期限的服用下去,而且由于长久服药,很多患者会发现优甲乐有很大的赖药性,往往一开始一天一片半,几年后就变成3片,又过几年就变成4片甚至更多。服用优甲乐不可擅自停药,一旦停药,甲状腺指标就会非常不给患者面子,T3、T4说降就降,各种并发症也随之而来。

2、常吃优甲乐要保护好你的“小心肝”:

长期服用优甲乐会增加心肌耗养量,增加心脏和肾脏的负担,所以服用优甲乐的患者应该留意心脏病和身体水肿。虽然优甲乐在服用上明确一些心绞痛、动脉硬化及冠心病、高血压和心肌梗塞的患者慎用,但甲减本身就会引起患者心血管方面的疾病,因此甲减患者在服用优甲乐时如履薄冰,需要十分的谨慎,稍有不慎就会出现不堪设想的后果。另外,长期服用优甲乐还会导致肝功异常,转氨酶升高。因此,临床中经常有一些甲减患者会配合护肝类的药物一起服用。

3、优甲乐会导致患者出现过敏反应:

一些患者服用优甲乐后,会出现浑身起红疹的症状,且还伴有严重的发痒,有过敏体质的患者则表现的更明显。

4、过量会引起和甲亢类似的症状:

优甲乐会引起心动过速、心悸、心绞痛、心律失常、头疼、神经质、兴奋不安、失眠、骨骼肌痉挛、肌无力、震颤、出汗潮红、怕热、腹泻、呕吐等类似甲亢的症状。

如何应对优甲乐的副作用

对于优甲乐的副作用,其实,医生们主要还是对症施药,要么调整药量,要么针对肝肾等损伤问题再行开药。要摆脱优甲乐的副作用,关键还是将疾病彻底治愈。而对于甲状腺腺体全部切除者,只能终身吃药代替缺失的甲状腺激素。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824330, encodeId=6c4d182433062, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Oct 05 10:44:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765084, encodeId=7fc41e65084a1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Nov 24 08:44:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374368, encodeId=e1313e4368f3, content=有依据吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13b12197383, createdName=120a8388m67(暂无昵称), createdTime=Fri Oct 25 08:24:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341323, encodeId=f58f13413236f, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Sep 07 03:44:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372311, encodeId=9b643e231174, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 05 12:49:01 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824330, encodeId=6c4d182433062, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Oct 05 10:44:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765084, encodeId=7fc41e65084a1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Nov 24 08:44:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374368, encodeId=e1313e4368f3, content=有依据吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13b12197383, createdName=120a8388m67(暂无昵称), createdTime=Fri Oct 25 08:24:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341323, encodeId=f58f13413236f, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Sep 07 03:44:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372311, encodeId=9b643e231174, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 05 12:49:01 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824330, encodeId=6c4d182433062, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Oct 05 10:44:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765084, encodeId=7fc41e65084a1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Nov 24 08:44:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374368, encodeId=e1313e4368f3, content=有依据吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13b12197383, createdName=120a8388m67(暂无昵称), createdTime=Fri Oct 25 08:24:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341323, encodeId=f58f13413236f, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Sep 07 03:44:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372311, encodeId=9b643e231174, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 05 12:49:01 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-10-25 120a8388m67(暂无昵称)

    有依据吗?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1824330, encodeId=6c4d182433062, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Oct 05 10:44:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765084, encodeId=7fc41e65084a1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Nov 24 08:44:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374368, encodeId=e1313e4368f3, content=有依据吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13b12197383, createdName=120a8388m67(暂无昵称), createdTime=Fri Oct 25 08:24:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341323, encodeId=f58f13413236f, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Sep 07 03:44:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372311, encodeId=9b643e231174, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 05 12:49:01 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1824330, encodeId=6c4d182433062, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Oct 05 10:44:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765084, encodeId=7fc41e65084a1, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Nov 24 08:44:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374368, encodeId=e1313e4368f3, content=有依据吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13b12197383, createdName=120a8388m67(暂无昵称), createdTime=Fri Oct 25 08:24:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341323, encodeId=f58f13413236f, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Sep 07 03:44:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372311, encodeId=9b643e231174, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 05 12:49:01 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-05 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

NEJM:静脉曲张治疗的五年结局比较

由此可见,在这项治疗静脉曲张的随机试验中,激光消融或手术治疗5年后的疾病特异性生活质量优于泡沫硬化治疗。大多数概率成本效益模型迭代有利于激光消融,每个QALY的意愿支付率为20000欧元(28433美元)。

NEJM:吸入GM-CSF治疗肺泡蛋白沉积症

由此可见,在这项随机对照试验中,吸入重组人GM-CSF与动脉氧张力实验室结果改善相关,并未发现临床益处。

Oncologist:扎心了,老铁!这5大原因,哪些戳中了肿瘤医生的心?

美国和欧洲均对卫生专业人员,包括肿瘤医生在内,对其工作倦怠和职业满意度进行了广泛的研究,但对于中国肿瘤医生的情况我们知之甚少。为此,中山大学附属肿瘤医院张力教授团队开展了一项全国性的调查,以评估中国肿瘤医生的职业倦怠情况和职业满意度。其中有827名肿瘤医生(51.0%)有职业倦怠,最主要的5大原因包括:患者治愈率低、致力于患者治疗的时间长、每周夜班次数多、为门诊返诊分配的时间较少、每年更多的周末轮

LANCET:确认!这种常见更年期治疗与乳腺癌风险有关

激素治疗是女性更年期常见的干预方式之一,有助于改善女性因激素变化而引起的经期紊乱、潮热出汗、骨质流失、心血管代谢功能变化等。然而,激素治疗是否会增加乳腺癌风险,一直是临床担忧的问题,且证据不一。

Cell:解惑!肿瘤坏死因子拮抗剂治疗不明原因肠炎为何经常无效?

克罗恩病是一种不明原因的肠炎,属于消化道慢性炎症,最终可能导致消化系统损伤甚至是功能丧失。其致病因素多种多样,比如高脂高糖饮食,不规律且快节奏的现代生活方式,遗传因素等等,这些因素可以引起消化道免疫系统异常活化,导致肠炎。近年来,诸多工作力图阐明肠炎发生发展的分子机制,并寻找治愈缓解的方法。而这些工作,往往建立在经典的以“抗体标记蛋白质”的研究方法上。当然了,单细胞测序技术的运用,为这一领域 ,带

切断能量、切断氧气、切断营养“饿死癌细胞”的正确打开方式

早在公元前5000年,人类就发现了最古老的癌症病例。此后的时间内,人类一直在与癌症漫长的争斗。目前,针对癌症的治疗已经不仅仅局限于常规的手术、化疗、放疗,越来越多的研究涉及到激素、微生物、昼夜节奏以及肿瘤微环境等诸多领域,致力于方方面面瓦解肿瘤;而在这其中,“饿死癌细胞”最引人关注。